Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Despite macro risks, Nvidia's impressive Q4 earnings and strong revenue outlook indicate significant growth potential. Check ...

U.S. President Donald Trump said Le Pen's conviction is a "very big" deal. "She was banned for running for five years, and ...

Rexford Industrial has seen a significant price decline but offers a 4.3% dividend yield. Learn more about REXR stock and why ...

KULR Technology reported fourth quarter and full-year 2024 results ahead of consensus expectations. See why I rate KULR stock ...

Nebius struggles with limited cash reserves and unrealistic revenue growth targets. Click here to find out why NBIS stock is ...

Hudbay Minerals is improving its operations and has a very strong balance sheet, allowing it to pay down debt. Learn why HBM ...

EHang's growth prospects are favorable, and the stock trades at a discount to its peers. Click here to see why EH is a Buy.

Economic uncertainty is rising. Click here to read two ETFs investors should consider during heightened uncertainty.

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding ...

Lument Finance Trust faces shrinking earnings, rising defaults, and credit risks. Click here to read why LFT stock is a Hold.

Paladin Energy stock dropped 37% yet shows future growth potential with acquisitions and a strong balance sheet. Read here ...